Features of the COPD course in patients with different alleles of C79G (rs1072714) of ADRB2 gene

  • Y. M. Mostovoy National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • K. D. Dmytriiev National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • N. S. Slepchenko National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: COPD, ADRB2, polymorphism, clinical course, exacerbation.

Abstract

Chronic obstructive pulmonary disease (COPD) is a widely spread disease, that can be prevented and treated. As it was mentioned in the GOLD guidelines, genetic factors have a prominent impact on the development of COPD. A great amount of different genes is involved into the development of COPD. They influence processes of inflammation, fibrosis and regulation of airways reactivity. Polymorphism of ADRB2 gene is of a particular interest as it is associated with the development of COPD and response to beta-2 agonists, which are the main drugs used in the treatment of COPD. The aim of our study was to investigate an impact of the polymorphism of ADRB2 gene on the clinical course of COPD. We collected source data, medical history in all patients in order to assess smoking status and smoking experience, clinical group of COPD according to GOLD classification, total amount of exacerbations, exacerbations treated in in-patient and out-patient conditions, data about use of antibiotics, glucocorticosteroids and methylxanthines. Blood was collected in all patients for the genetic analysis of ADRB2 gene polymorphism. Among COPD patients 65 (65 %) had changes in ADRB2 gene. 26 patients (26 %) had mutation and 39 patients (39 %) had polymorphism of ADRB2 gene, which indicate possible relation of ADRB2 gene with the COPD development. Patients of group 1, C79C allele carriers, had milder COPD course, which presented with the significant difference in the of GOLD D patients in this group (17.14±7.13 %) and group 2, C79G allele carriers, (58.97±8.15 %) and group 3, G79G allele carriers, (34.61±9.59 %). Group 1 patients had lower amount of exacerbations (2.543±0.281) when compared to group 3 (2.963±0.273), and lower amount of hospital admissions (1.031±0.154) when compared to group 2 (1.332±0.167). Group 1 patients also used less antibiotics then other groups. So, ADRB2 gene polymorphism in C79G positions is a prognostic factor of the severity of COPD course. It is associated with the greater amount of exacerbations and hospitalizations and also greater antibiotic use.

References

[1] Abubakar, I. I., Tillmann, T., & Banerjee, A. (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 385(9963), 117-171. doi: 10.1016/S0140-6736(14)61682-2
[2] Dmytriiev, K., Mostovoy, Y., Slepchenko, N., Tsymbaliuk, N., Sidorov, A., Dmytriiev, D., & Shostatska, M. (2020). “Smoking” vs “non-smoking” COPD: how dramatic is the difference?. European Respiratory Journal, 56(64), 1043. doi: 10.1183/13993003.congress-2020.1043
[3] Dmytriiev, K., Mostovoy, Y., Slepchenko, N., Tsymbaliuk, N., Sidorov, A., Dmytriiev, D., & Shostatska, M. (2020). Can reversibility determine clinical course in patients with COPD?. European Respiratory Journal, 56(64), 1041. doi: 10.1183/13993003.congress-2020.1041
[4] GBD 2015 Chronic Respiratory Disease Collaborators. (2017). Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Respiratory Medicine, 5(9), 691-706. doi: 10.1016/S2213-2600(17)30293-X
[5] Gorovenko, N. G., Stupnytska, G. Y., & Podolskaya, S. V. (2015). Асоціація поліморфного варіанта гена ADRB2 (C79G) з розвитком та перебігом хронічного обструктивного захворювання легень [Association of polymorphic variant of the gene adrb2 (C79G) with the development and course of chronic obstructive pulmonary disease]. Український пульмонологічний журнал – Ukr. Pulmonol. J., (3), 25-30.
[6] Hegab, A. E., Sakamoto, T., Saitoh, W., Massoud, H. H., Massoud, H. M., Hassanein, K. M., & Sekizawa, K. (2004). Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest, 126(6), 1832-1839. doi: 10.1378/chest.126.6.1832
[7] Hizawa, N., Makita, H., Nasuhara, Y., Betsuyaku, T., Itoh, Y., Nagai, K., ... & Nishimura, M. (2007). β2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest, 132(5), 1485-1492. doi: 10.1378/chest.07-1103
[8] Karimi, L., Lahousse, L., Ghanbari, M., Terzikhan, N., Uitterlinden, A. G., van der Lei, J., ... & Verhamme, K. (2019). β2-Adrenergic Receptor (ADRB2) Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study. Journal of clinical medicine, 8(11), 1835. doi: 10.3390/jcm8111835
[9] Kim, W. J., Oh, Y. M., Sung, J., Kim, T. H., Huh, J. W., Jung, H., ... & Do Lee, S. (2008). Lung Function Response to 12-week Treatment with Combined Inhalation of Long-acting β 2 Agonist and Glucocorticoid According to ADRB2 Polymorphism in Patients with Chronic Obstructive Pulmonary Disease. Lung, 186(6), 381-386. doi: 10.1007/s00408-008-9103-9
[10] Lamprecht, B., McBurnie, M. A., Vollmer, W. M., Gudmundsson, G., Welte, T., Nizankowska-Mogilnicka, E., ... & BOLD Collaborative Research Group. (2011). COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest, 139(4), 752-763. doi: 10.1378/chest.10-1253
[11] Li, J. X., Fu, W. P., Zhang, J., Zhang, X. H., Sun, C., Dai, L. M., ... & Zhang, Y. P. (2018). A functional SNP upstream of the ADRB2 gene is associated with COPD. International journal of chronic obstructive pulmonary disease, 13, 917-925. doi: 10.2147/COPD.S151153
[12] Lopez, A. D., Shibuya, K., Rao, C., Mathers, C. D., Hansell, A. L., Held, L. S., ... & Buist, S. (2006). Chronic obstructive pulmonary disease: current burden and future projections. European Respiratory Journal, 27(2), 397-412. doi: 10.1183/09031936.06.00025805
[13] Nojiri, M., Mizuno, S., Nishiki, K., Kato, R., Nakagawa, K., Oikawa, T., ... & Toga, H. (2018). ADRB2 gene polymorphism and emphysema heterogeneity can modulate bronchodilator response in patients with emphysema. Pulmonary pharmacology & therapeutics, 48, 80-87. doi: 10.1016/j.pupt.2017.09.004
[14] Pauwels, R. A., Buist, A. S., Calverley, P. M., Jenkins, C. R., & Hurd, S. S. (2001). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American journal of respiratory and critical care medicine, 163(5), 1256-1276. doi: 10.1164/ajrccm.163.5.2101039
[15] Silverman, E. K. (2020). Genetics of COPD. Annual review of physiology, 82, 413-431. doi: 10.1146/annurev-physiol-021317-121224
[16] Stupnytska, G., Gorovenko, N., Podolska, S., Kit, Z., Sheremet, M., Kovtun, A., & Nesterovska, O. (2018, September). Association of the ADRB2 gene polymorphic variant C79G (rs1072714) with the course of chronic obstructive pulmonary disease in obese and non-obese patients. In CBU International Conference Proceedings (Vol. 6, pp. 960-965). doi: 10.12955/cbup.v6.1278
[17] Vacca, G., Schwabe, K., Dück, R., Hlawa, H. P., Westphal, A., Pabst, S., ... & Gillissen, A. (2009). Polymorphisms of the ß2 adrenoreceptor gene in chronic obstructive pulmonary disease. Therapeutic advances in respiratory disease, 3(1), 3-10. doi: 10.1177/1753465809102553
[18] Zhao, H., Wu, X., Dong, C. L., Wang, B. Y., Zhao, J., & Cao, X. E. (2017). Association Between ADRB2 Genetic Polymorphisms and the Risk of Chronic Obstructive Pulmonary Disease: A Case–Control Study in a Chinese Population. Genetic testing and molecular biomarkers, 21(8), 491-496. doi: 10.1089/gtmb.2017.0030
Published
2021-03-27
How to Cite
Mostovoy, Y. M., Dmytriiev, K. D., & Slepchenko, N. S. (2021). Features of the COPD course in patients with different alleles of C79G (rs1072714) of ADRB2 gene. Biomedical and Biosocial Anthropology, (42), 39-43. https://doi.org/10.31393/bba42-2021-07

Most read articles by the same author(s)